The study aims to determine the effect of SVT-40776, a novel substituted quinuclidine derivative with high M3 receptor affinity, on the different human muscarinic receptors through radioligand binding assays and to evaluate its activity on the intra-vesical and arterial pressure in anesthetized animals. SVT-40776 exhibits high affinity, in the sub-nanomolar range, for the human M3 muscarinic receptor, being the most potent ligand among all the reference compounds assayed. It also shows the highest selectivity of human M3 vs. the M2 subtype, among all the reference antagonists tested. SVT-40766 is the most potent compound inhibiting the bladder contractions, at the very low dose of 17.1 nmol/kg i.v.